June 13, 2006 > DiscoveRx enters into custom labeling and profiling services

FREMONT (BUSINESS WIRE), June 6_DiscoveRx Corporation, an established provider of HitHunter(TM) assays, announced the launch of a custom labeling and profiling service for kinases and proteases. These services are yet another major step in their strategy to provide broader access to DiscoveRx's proprietary technology platform, Enzyme Fragment Complementation (EFC). The technology, marketed as the HitHunter(TM) line of products, has already been widely utilized by drug discovery researchers and well established as a high quality screening approach.

DiscoveRx will focus on creating custom labeling and assay development solutions for drug development customers, offering companies a strategic outsourcing option for kinase and protease assays that will dramatically increase the pace of drug discovery. Services include labeling of biomolecules with their beta-galactosidase Enzyme Donor (ED) tag for unactive and active kinase screening as well as synthesizing protease substrates with ED tags to enable chemiluminescent assays for new protease targets.

EFC assays are simple, homogeneous, non-radioactive assays that have been adopted in 384, 1536 and 3456 formats. DiscoveRx offers a series of novel assays for detecting second messengers, kinases and proteases. Exquisite assay sensitivity coupled to robust Z' factor and signal to background ratios make them the assays of choice for HTS. Amongst the technology portfolio, kinase binding assays have attracted wide attention since these unique assay formats allow customers to screen against active and/or unactive kinases.

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont. DiscoveRx pioneered the use of beta-galactosidase enzyme fragment complementation in biochemical assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and our products have been adopted in pharmaceutical and biotech drug screening initiatives for a number of years. For more information, visit www.discoverx.com.